Format

Send to

Choose Destination
Stem Cells Dev. 2015 Jun 1;24(11):1284-96. doi: 10.1089/scd.2014.0540. Epub 2015 Mar 31.

Stem cell-derived systems in toxicology assessment.

Author information

1
1University of Applied Sciences Northwestern Switzerland, School of Life Sciences, Muttenz, Switzerland.
2
2iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
3
3Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal.
4
4Division of Toxicology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands.
5
5Bayer Pharma AG, Global Drug Discovery-Global Early Development, Wuppertal, Germany.
6
6European Commission Joint Research Centre, Institute for Health and Consumer Protection, EURL ECVAM, Ispra, Italy.
7
7BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany.
8
9Institut for Neurophysiology, University of Cologne, Cologne, Germany.
9
10Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
10
11Division of Physiology, Department of Physiology and Medical Physics, Innsbruck Medical University, Innsbruck, Austria.
11
12InSphero AG, Schlieren, Switzerland.
12
13European Partnership for Alternative Approaches to Animal Testing (EPAA), B-Brussels, Belgium.
13
14Syngenta Ltd., Product Safety, Jealott's Hill International Research Station, Berkshire, United Kingdom.
14
15Dipartimento di Scienze Biochimiche e Cliniche, Università degli Studi di Milano, Milano, Italy.
15
16Centro Internazionale per gli Antiparassitari e la Prevenzione Sanitaria, Luigi Sacco Hospital, Milano, Italy.
16
17F. Hoffmann-La Roche Ltd., Innovation Center Basel, Pharmaceutical Sciences, Basel, Switzerland.
17
18Pfizer Worldwide Research and Development, Cambridge, Massachusetts.
18
19Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.

Abstract

Industrial sectors perform toxicological assessments of their potential products to ensure human safety and to fulfill regulatory requirements. These assessments often involve animal testing, but ethical, cost, and time concerns, together with a ban on it in specific sectors, make appropriate in vitro systems indispensable in toxicology. In this study, we summarize the outcome of an EPAA (European Partnership of Alternatives to Animal Testing)-organized workshop on the use of stem cell-derived (SCD) systems in toxicology, with a focus on industrial applications. SCD systems, in particular, induced pluripotent stem cell-derived, provide physiological cell culture systems of easy access and amenable to a variety of assays. They also present the opportunity to apply the vast repository of existing nonclinical data for the understanding of in vitro to in vivo translation. SCD systems from several toxicologically relevant tissues exist; they generally recapitulate many aspects of physiology and respond to toxicological and pharmacological interventions. However, focused research is necessary to accelerate implementation of SCD systems in an industrial setting and subsequent use of such systems by regulatory authorities. Research is required into the phenotypic characterization of the systems, since methods and protocols for generating terminally differentiated SCD cells are still lacking. Organotypical 3D culture systems in bioreactors and microscale tissue engineering technologies should be fostered, as they promote and maintain differentiation and support coculture systems. They need further development and validation for their successful implementation in toxicity testing in industry. Analytical measures also need to be implemented to enable compound exposure and metabolism measurements for in vitro to in vivo extrapolation. The future of SCD toxicological tests will combine advanced cell culture technologies and biokinetic measurements to support regulatory and research applications. However, scientific and technical hurdles must be overcome before SCD in vitro methods undergo appropriate validation and become accepted in the regulatory arena.

PMID:
25675366
DOI:
10.1089/scd.2014.0540
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center